The NHS has launched a clinical trial of puberty blockers for children, reigniting debate over the safety, ethics and evidence base for hormone treatment in gender-diverse young people. The study, part of a structured research programme, aims to provide clearer data on long-term outcomes from puberty suppression, including developmental, metabolic and psychological impacts.
Puberty blockers, or gonadotrophin-releasing hormone (GnRH) analogues, were formerly prescribed more widely in the UK. In March 2024, NHS England restricted their use to research settings, following the Cass Review, which highlighted major knowledge gaps on effects including bone density, fertility, cognition and mental health. Health Secretary Wes Streeting described the decision as 'evidence-led,' arguing that rigorous oversight is essential.
